{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:11:30Z","timestamp":1791141090567,"version":"4.1.0"},"reference-count":267,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Prostate cancer (PCa) is the second most common cancer in men. Common treatments include active surveillance, surgery, or radiation. Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease or biochemical recurrence, such as castration-resistant prostate cancer (CRPC), but they are not considered curative because PCa cells eventually develop drug resistance. The latter is achieved through various cellular mechanisms that ultimately circumvent the pharmaceutical\u2019s mode of action. The need for novel therapeutic approaches is necessary under these circumstances. An alternative way to treat PCa is by repurposing of existing drugs that were initially intended for other conditions. By extrapolating the effects of previously approved drugs to the intracellular processes of PCa, treatment options will expand. In addition, drug repurposing is cost-effective and efficient because it utilizes drugs that have already demonstrated safety and efficacy. This review catalogues the drugs that can be repurposed for PCa in preclinical studies as well as clinical trials.<\/jats:p>","DOI":"10.3390\/medsci10010015","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T08:22:19Z","timestamp":1645431739000},"page":"15","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-2595","authenticated-orcid":false,"given":"Hisham F.","family":"Bahmad","sequence":"first","affiliation":[{"name":"Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6922-3216","authenticated-orcid":false,"given":"Timothy","family":"Demus","sequence":"additional","affiliation":[{"name":"Division of Urology, Columbia University, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya M.","family":"Moubarak","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Cell Biology, and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon"},{"name":"CNRS, IBGC, UMR5095, Universite de Bordeaux, F-33000 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-1176","authenticated-orcid":false,"given":"Darine","family":"Daher","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Alvarez Moreno","sequence":"additional","affiliation":[{"name":"Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Polit","sequence":"additional","affiliation":[{"name":"Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lopez","sequence":"additional","affiliation":[{"name":"Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8749-1222","authenticated-orcid":false,"given":"Ali","family":"Merhe","sequence":"additional","affiliation":[{"name":"Department of Urology, Jackson Memorial Hospital, University of Miami, Leonard M. Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-9324","authenticated-orcid":false,"given":"Wassim","family":"Abou-Kheir","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Cell Biology, and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan M.","family":"Nieder","sequence":"additional","affiliation":[{"name":"Division of Urology, Columbia University, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"},{"name":"Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Poppiti","sequence":"additional","affiliation":[{"name":"Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"},{"name":"Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumna","family":"Omarzai","sequence":"additional","affiliation":[{"name":"Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA"},{"name":"Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer Statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/S0022-5347(01)62201-8","article-title":"Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes","volume":"160","author":"Stamey","year":"1998","journal-title":"J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.juro.2011.03.119","article-title":"Significance of prostate adenocarcinoma perineural invasion on biopsy in patients who are otherwise candidates for active surveillance","volume":"186","author":"Carter","year":"2011","journal-title":"J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"495.e1","DOI":"10.1016\/j.urolonc.2021.01.007","article-title":"Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy","volume":"39","author":"Rakic","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-1-4615-3398-6_18","article-title":"Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases","volume":"324","author":"Harada","year":"1992","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/01.ju.0000158039.94467.5d","article-title":"Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen","volume":"173","author":"Karakiewicz","year":"2005","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MOU.0000000000000031","article-title":"Standards for prostate biopsy","volume":"24","author":"Bjurlin","year":"2014","journal-title":"Curr. Opin. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0094-0143(05)70386-4","article-title":"Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control","volume":"24","author":"Pound","year":"1997","journal-title":"Urol. Clin. N. Am."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","article-title":"Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement","volume":"34","author":"Chen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO\/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options","volume":"199","author":"Sanda","year":"2018","journal-title":"J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JU.0000000000001375","article-title":"Advanced Prostate Cancer: AUA\/ASTRO\/SUO Guideline PART I","volume":"205","author":"Lowrance","year":"2021","journal-title":"J. Urol."},{"key":"ref_13","first-page":"S273","article-title":"Management of biochemically recurrent prostate cancer following local therapy","volume":"20","author":"Kolodziej","year":"2014","journal-title":"Am. J. Manag. Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-5347(05)63946-8","article-title":"Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer","volume":"169","author":"Han","year":"2003","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: A systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1172\/JCI115954","article-title":"Molecular genetics of steroid 5 alpha-reductase 2 deficiency","volume":"90","author":"Thigpen","year":"1992","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1001\/jama.1947.62890170001007","article-title":"Cancer of the bladder and prostate","volume":"135","author":"HUGGINS","year":"1947","journal-title":"J. Am. Med. Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11912-017-0568-7","article-title":"Mechanisms of Therapeutic Resistance in Prostate Cancer","volume":"19","author":"Nakazawa","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.bbadis.2018.02.016","article-title":"Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2","volume":"1864","author":"Tsai","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fonc.2019.00131","article-title":"EMT Markers in Locally-Advanced Prostate Cancer: Predicting Recurrence?","volume":"9","author":"Cheaito","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"40554","DOI":"10.1038\/srep40554","article-title":"Androgen receptor gene polymorphisms and risk of prostate cancer: A meta-analysis","volume":"7","author":"Weng","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Maitland, N.J. (2021). Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?. Cancers, 13.","DOI":"10.3390\/cancers13020327"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/2159-8290.CD-17-0867","article-title":"Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth","volume":"8","author":"Pearson","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1158\/0008-5472.CAN-18-2812","article-title":"Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer","volume":"79","author":"Li","year":"2019","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/onc.2009.496","article-title":"Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase","volume":"29","author":"Yamamoto","year":"2010","journal-title":"Oncogene"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1158\/0008-5472.CAN-11-3132","article-title":"Pten loss and RAS\/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem\/progenitor cells","volume":"72","author":"Mulholland","year":"2012","journal-title":"Cancer Res."},{"key":"ref_28","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_29","first-page":"3051","article-title":"Targeting AKT\/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model","volume":"118","author":"Kinkade","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1038\/onc.2013.461","article-title":"TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c","volume":"33","author":"Kim","year":"2014","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1158\/0008-5472.CAN-17-0686","article-title":"Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion","volume":"77","author":"Yang","year":"2017","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.18632\/oncotarget.2953","article-title":"Prostate cancer stem cells: Deciphering the origins and pathways involved in prostate tumorigenesis and aggression","volume":"6","author":"Rybak","year":"2015","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.critrevonc.2017.02.025","article-title":"Role of hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy of colorectal cancer","volume":"113","author":"Vadde","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"108497","DOI":"10.1016\/j.steroids.2019.108497","article-title":"Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer","volume":"152","author":"Johnson","year":"2019","journal-title":"Steroids"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/clpt.2012.236","article-title":"Phenotypic vs. target-based drug discovery for first-in-class medicines","volume":"93","author":"Swinney","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrd4336","article-title":"The discovery of first-in-class drugs: Origins and evolution","volume":"13","author":"Eder","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","unstructured":"Phillips, D.J. (2021, January 11). Pfizer\u2019s Expiring Viagra Patent Adversely Affects Other Drugmakers Too. Available online: https:\/\/www.forbes.com\/sites\/investor\/2013\/12\/20\/pfizers-expiring-viagra-patent-adversely-affects-other-drugmakers-too\/?sh=5349531468d4."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/toxsci\/kfr088","article-title":"Thalidomide: The tragedy of birth defects and the effective treatment of disease","volume":"122","author":"Kim","year":"2011","journal-title":"Toxicol. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"105948","DOI":"10.1016\/j.ijantimicag.2020.105948","article-title":"Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence","volume":"55","author":"Wang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1126\/science.abb9332","article-title":"Rapid repurposing of drugs for COVID-19","volume":"368","author":"Guy","year":"2020","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"105969","DOI":"10.1016\/j.ijantimicag.2020.105969","article-title":"Drug repositioning is an alternative for the treatment of coronavirus COVID-19","volume":"55","author":"Serafin","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41391-020-0262-y","article-title":"Crosstalk between COVID-19 and prostate cancer","volume":"23","author":"Bahmad","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"key":"ref_49","first-page":"219","article-title":"Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia","volume":"43","author":"Sun","year":"2020","journal-title":"Chin. J. Tuberc. Respir. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd.2018.92","article-title":"Overcoming the legal and regulatory barriers to drug repurposing","volume":"18","author":"Breckenridge","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"654","DOI":"10.7150\/ijbs.9224","article-title":"Recent advances in drug repositioning for the discovery of new anticancer drugs","volume":"10","author":"Shim","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"D351","DOI":"10.1093\/nar\/gkm843","article-title":"ChemBank: A small-molecule screening and cheminformatics resource database","volume":"36","author":"Seiler","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr. Protoc. Bioinform."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"D789","DOI":"10.1093\/nar\/gku1205","article-title":"OMIM.org: Online Mendelian Inheritance in Man (OMIM(R)), an online catalog of human genes and genetic disorders","volume":"43","author":"Amberger","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","article-title":"PubChem Substance and Compound databases","volume":"44","author":"Kim","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/clpt.2013.1","article-title":"Computational drug repositioning: From data to therapeutics","volume":"93","author":"Hurle","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nbt.2151","article-title":"Use of genome-wide association studies for drug repositioning","volume":"30","author":"Sanseau","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/d41586-018-05462-w","article-title":"New human gene tally reignites debate","volume":"558","author":"Willyard","year":"2018","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1755-8794-8-S2-S1","article-title":"Novel therapeutics for coronary artery disease from genome-wide association study data","volume":"8","author":"Grover","year":"2015","journal-title":"BMC Med. Genom."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/nbt.2758","article-title":"Rational drug repositioning by medical genetics","volume":"31","author":"Wang","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1093\/hmg\/ddw160","article-title":"Pathway and network-based strategies to translate genetic discoveries into effective therapies","volume":"25","author":"Greene","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ng.717","article-title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn\u2019s disease susceptibility loci","volume":"42","author":"Franke","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Wu, H., Gao, L., Dong, J., and Yang, X. (2014). Detecting overlapping protein complexes by rough-fuzzy clustering in protein-protein interaction networks. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091856"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Yu, L., Huang, J., Ma, Z., Zhang, J., Zou, Y., and Gao, L. (2015). Inferring drug-disease associations based on known protein complexes. BMC Med. Genom., 8.","DOI":"10.1186\/1755-8794-8-S2-S2"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1080\/07391102.2015.1060161","article-title":"Identification of new candidate drugs for lung cancer using chemical-chemical interactions, chemical-protein interactions and a K-means clustering algorithm","volume":"34","author":"Lu","year":"2016","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"036103","DOI":"10.1103\/PhysRevE.83.036103","article-title":"Unfolding communities in large complex networks: Combining defensive and offensive label propagation for core extraction","volume":"83","author":"Subelj","year":"2011","journal-title":"Phys. Rev. E Stat. Nonlinear Soft Matter Phys."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.artmed.2014.11.003","article-title":"DrugNet: Network-based drug-disease prioritization by integrating heterogeneous data","volume":"63","author":"Martinez","year":"2015","journal-title":"Artif. Intell. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"E5207","DOI":"10.1073\/pnas.1617467114","article-title":"Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing","volume":"114","author":"Fei","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41419-021-04027-6","article-title":"CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer","volume":"12","author":"Lei","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Tsujino, T., Komura, K., Inamoto, T., and Azuma, H. (2021). CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312777"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13831","DOI":"10.1038\/s41598-020-70764-x","article-title":"Chemogenomic screening identifies the Hsp70 co-chaperone DNAJA1 as a hub for anticancer drug resistance","volume":"10","author":"Blackman","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2006.09.005","article-title":"Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators","volume":"10","author":"Hieronymus","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.drudis.2012.07.014","article-title":"Transcriptional data: A new gateway to drug repositioning?","volume":"18","author":"Iorio","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/bib\/bbr013","article-title":"Exploiting drug-disease relationships for computational drug repositioning","volume":"12","author":"Dudley","year":"2011","journal-title":"Brief. Bioinform."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","article-title":"Discovery and preclinical validation of drug indications using compendia of public gene expression data","volume":"3","author":"Sirota","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"96ra76","DOI":"10.1126\/scitranslmed.3002648","article-title":"Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease","volume":"3","author":"Dudley","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_79","first-page":"527","article-title":"Identifying new antiepileptic drugs through genomics-based drug repurposing","volume":"26","author":"Mirza","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"17784","DOI":"10.1038\/srep17784","article-title":"Drug Signature-based Finding of Additional Clinical Use of LC28-0126 for Neutrophilic Bronchial Asthma","volume":"5","author":"Shin","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"E3725","DOI":"10.1073\/pnas.1520289113","article-title":"Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis","volume":"113","author":"Malcomson","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"791","DOI":"10.15252\/msb.20145486","article-title":"Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia","volume":"11","author":"Wagner","year":"2015","journal-title":"Mol. Syst. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","article-title":"Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance","volume":"10","author":"Wei","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nchembio0807-447","article-title":"Systems chemical biology","volume":"3","author":"Oprea","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.4161\/auto.6.8.13551","article-title":"Identification of small molecules enhancing autophagic function from drug network analysis","volume":"6","author":"Iorio","year":"2010","journal-title":"Autophagy"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nrd1549","article-title":"Docking and scoring in virtual screening for drug discovery: Methods and applications","volume":"3","author":"Kitchen","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/17460441.2016.1190706","article-title":"Using reverse docking for target identification and its applications for drug discovery","volume":"11","author":"Lee","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1021\/jm300576q","article-title":"Predicting new indications for approved drugs using a proteochemometric method","volume":"55","author":"Dakshanamurthy","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.1158140","article-title":"Drug target identification using side-effect similarity","volume":"321","author":"Campillos","year":"2008","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Yang, L., and Agarwal, P. (2011). Systematic drug repositioning based on clinical side-effects. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028025"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jbi.2018.09.015","article-title":"PISTON: Predicting drug indications and side effects using topic modeling and natural language processing","volume":"87","author":"Jang","year":"2018","journal-title":"J. Biomed. Inform."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement","volume":"164","author":"Force","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.drudis.2011.09.019","article-title":"Retrospective clinical analysis for drug rescue: For new indications or stratified patient groups","volume":"17","author":"Cavalla","year":"2012","journal-title":"Drug Discov. Today"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrg3208","article-title":"Mining electronic health records: Towards better research applications and clinical care","volume":"13","author":"Jensen","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1038\/srep08580","article-title":"Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records","volume":"5","author":"Paik","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_98","first-page":"166","article-title":"A Simple Text Mining Approach for Ranking Pairwise Associations in Biomedical Applications","volume":"2017","author":"Kuusisto","year":"2017","journal-title":"AMIA Summits Transl. Sci. Proc."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Li, J., Zhu, X., and Chen, J.Y. (2009). Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts. PLoS Comput. Biol., 5.","DOI":"10.1371\/journal.pcbi.1000450"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Gramatica, R., Di Matteo, T., Giorgetti, S., Barbiani, M., Bevec, D., and Aste, T. (2014). Graph theory enables drug repurposing--how a mathematical model can drive the discovery of hidden mechanisms of action. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0084912"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Zhang, M., Schmitt-Ulms, G., Sato, C., Xi, Z., Zhang, Y., Zhou, Y., St George-Hyslop, P., and Rogaeva, E. (2016). Drug Repositioning for Alzheimer\u2019s Disease Based on Systematic \u2019omics\u2019 Data Mining. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168812"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11864-020-00805-0","article-title":"Drug Repurposing in Medulloblastoma: Challenges and Recommendations","volume":"22","author":"Hammoud","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10555-019-09840-2","article-title":"Drug repurposing towards targeting cancer stem cells in pediatric brain tumors","volume":"39","author":"Bahmad","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1369\/00221554211025482","article-title":"Repurposing of Anticancer Stem Cell Drugs in Brain Tumors","volume":"69","author":"Bahmad","year":"2021","journal-title":"J. Histochem. Cytochem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/clpt.2010.286","article-title":"Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000\u20132009","volume":"89","author":"Kaitin","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1464-410X.2010.09514.x","article-title":"Trends in the treatment of localized prostate cancer using supplemented cancer registry data","volume":"107","author":"Hamilton","year":"2011","journal-title":"BJU Int."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1001\/jama.2013.6882","article-title":"Use of advanced treatment technologies among men at low risk of dying from prostate cancer","volume":"309","author":"Jacobs","year":"2013","journal-title":"JAMA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1464-410X.2010.09594.x","article-title":"Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy","volume":"107","author":"Walz","year":"2011","journal-title":"BJU Int."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.juro.2007.03.105","article-title":"Radical prostatectomy for clinically localized, high risk prostate cancer: Critical analysis of risk assessment methods","volume":"178","author":"Yossepowitch","year":"2007","journal-title":"J. Urol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa1011967","article-title":"Radical prostatectomy versus watchful waiting in early prostate cancer","volume":"364","author":"Holmberg","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1113162","article-title":"Radical prostatectomy versus observation for localized prostate cancer","volume":"367","author":"Wilt","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2214\/AJR.09.2579","article-title":"Challenges in clinical prostate cancer: Role of imaging","volume":"192","author":"Kelloff","year":"2009","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.2741\/2311","article-title":"Biology and clinical management of prostate cancer bone metastasis","volume":"12","author":"Ye","year":"2007","journal-title":"Front. Biosci."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Mollica, V., Rizzo, A., Rosellini, M., Marchetti, A., Ricci, A.D., Cimadamore, A., Scarpelli, M., Bonucci, C., Andrini, E., and Errani, C. (2021). Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. Cancers, 13.","DOI":"10.3390\/cancers13030546"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10555-013-9480-2","article-title":"Bone-targeting agents in prostate cancer","volume":"33","author":"Suzman","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ctrv.2016.09.017","article-title":"Early use of chemotherapy in metastatic prostate cancer","volume":"55","author":"Markowski","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_118","first-page":"122","article-title":"Current clinical challenges in prostate cancer","volume":"2","author":"Silberstein","year":"2013","journal-title":"Transl. Androl. Urol."},{"key":"ref_119","first-page":"S31","article-title":"Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer","volume":"102","author":"Bostwick","year":"1994","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1590\/S1677-55382009000500003","article-title":"Prostatic specific antigen for prostate cancer detection","volume":"35","author":"Nogueira","year":"2009","journal-title":"Int. Braz. J. Urol."},{"key":"ref_121","first-page":"207","article-title":"Newer potential biomarkers in prostate cancer","volume":"9","author":"Wright","year":"2007","journal-title":"Rev. Urol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0094-0143(03)00057-0","article-title":"PSA markers in prostate cancer detection","volume":"30","author":"Gretzer","year":"2003","journal-title":"Urol. Clin. N. Am."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/cncr.23373","article-title":"Active surveillance for early-stage prostate cancer: Review of the current literature","volume":"112","author":"Cooperberg","year":"2008","journal-title":"Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/jcp.2002.003954","article-title":"Molecular pathology of prostate cancer","volume":"58","author":"Hughes","year":"2005","journal-title":"J. Clin. Pathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.pcan.4500889","article-title":"The Charlson comorbidity score: A superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting","volume":"9","author":"Kastner","year":"2006","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-5347(05)00018-2","article-title":"Predicting life expectancy in men with clinically localized prostate cancer","volume":"175","author":"Cowen","year":"2006","journal-title":"J. Urol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/01.ju.0000117975.40782.95","article-title":"Long-term survival probability in men with clinically localized prostate cancer: A case-control, propensity modeling study stratified by race, age, treatment and comorbidities","volume":"171","author":"Tewari","year":"2004","journal-title":"J. Urol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2006.10.3820","article-title":"A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer","volume":"25","author":"Walz","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_129","first-page":"4363","article-title":"Screening for prostate cancer: An update","volume":"15","author":"Shariat","year":"2008","journal-title":"Can. J. Urol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1002\/cncr.20305","article-title":"Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma","volume":"100","author":"Eichelberger","year":"2004","journal-title":"Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.urology.2007.10.022","article-title":"Trends in Gleason score: Concordance between biopsy and prostatectomy over 15 years","volume":"72","author":"Rajinikanth","year":"2008","journal-title":"Urology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/j.sult.2007.05.002","article-title":"Advances in transrectal ultrasound imaging of the prostate","volume":"28","author":"Linden","year":"2007","journal-title":"Semin. Ultrasound CT MRI"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fphar.2018.00245","article-title":"Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?","volume":"9","author":"Nurgali","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1158\/1535-7163.MCT-17-0157","article-title":"Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic beta-catenin Signaling and EMT Progression","volume":"16","author":"Hafeez","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2147\/TCRM.S13883","article-title":"Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia","volume":"7","author":"Masumori","year":"2011","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00432-017-2367-9","article-title":"Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells","volume":"143","author":"Iwamoto","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e1097","DOI":"10.1097\/MD.0000000000001097","article-title":"Propranolol Reduces Cancer Risk: A Population-Based Cohort Study","volume":"94","author":"Chang","year":"2015","journal-title":"Medicine"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1158\/0008-5472.CAN-08-2530","article-title":"Inhibition of the Sodium Potassium Adenosine Triphosphatase Pump Sensitizes Cancer Cells to Anoikis and Prevents Distant Tumor Formation","volume":"69","author":"Simpson","year":"2009","journal-title":"Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1038\/s41598-018-25340-9","article-title":"Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression","volume":"8","author":"Peulen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"762178","DOI":"10.1155\/2015\/762178","article-title":"Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell lines","volume":"2015","author":"Olivan","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1074\/jbc.275.15.11397","article-title":"The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2","volume":"275","author":"Hsu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.celrep.2016.05.037","article-title":"A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors","volume":"15","author":"Gayvert","year":"2016","journal-title":"Cell Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13046-020-01723-7","article-title":"Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition","volume":"39","author":"Iannelli","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Salem, O., and Hansen, C.G. (2019). The Hippo Pathway in Prostate Cancer. Cells, 8.","DOI":"10.3390\/cells8040370"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"14328","DOI":"10.1074\/jbc.RA118.004442","article-title":"Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)","volume":"293","author":"Kong","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fonc.2017.00243","article-title":"Metformin: A Bridge between Diabetes and Prostate Cancer","volume":"7","author":"Zingales","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41391-018-0085-2","article-title":"The anticancer potential of metformin on prostate cancer","volume":"22","author":"Zaidi","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/pros.23000","article-title":"Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor","volume":"75","author":"Wang","year":"2015","journal-title":"Prostate"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"27819","DOI":"10.1038\/srep27819","article-title":"Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis","volume":"6","author":"Qi","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41416-019-0681-5","article-title":"Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment","volume":"122","author":"Rushworth","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-13-3296","article-title":"Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer","volume":"20","author":"Liu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(08)70334-6","article-title":"Anti-HIV drugs for cancer therapeutics: Back to the future?","volume":"10","author":"Chow","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"9698","DOI":"10.1038\/srep09698","article-title":"Nelfinavir and nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant prostate cancer","volume":"5","author":"Guan","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.phrs.2010.11.003","article-title":"Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers","volume":"63","author":"Lokeshwar","year":"2011","journal-title":"Pharmacol. Res."},{"key":"ref_155","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer","volume":"9","author":"Corey","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1158\/0008-5472.CAN-05-0487","article-title":"Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo","volume":"66","author":"Xia","year":"2006","journal-title":"Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1097-0045(20000401)43:1<31::AID-PROS5>3.0.CO;2-#","article-title":"Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture","volume":"43","author":"Liang","year":"2000","journal-title":"Prostate"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/jm301544x","article-title":"Development of new cathepsin B inhibitors: Combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives","volume":"56","author":"Sosic","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/jnci\/djq457","article-title":"Effect of nitroxoline on angiogenesis and growth of human bladder cancer","volume":"102","author":"Shim","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"39806","DOI":"10.18632\/oncotarget.5655","article-title":"Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: A crucial role on AMPK\/mTOR signaling pathway and the interplay with Chk2 activation","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_161","first-page":"95","article-title":"HIV protease inhibitors: A review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV AIDS"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/CCO.0b013e328363dfee","article-title":"Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention","volume":"25","author":"Gantt","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"19579","DOI":"10.1073\/pnas.0809763105","article-title":"Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_164","first-page":"21","article-title":"A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA","volume":"2","author":"Lin","year":"2014","journal-title":"Am. J. Cancer Ther. Pharmacol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1111\/bph.12800","article-title":"Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer","volume":"171","author":"Wang","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/138920106779116928","article-title":"Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: A new family of anti-cancer agents?","volume":"7","author":"Lupu","year":"2006","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"9362","DOI":"10.18632\/oncotarget.2433","article-title":"The fatty acid synthase inhibitor triclosan: Repurposing an anti-microbial agent for targeting prostate cancer","volume":"5","author":"Sadowski","year":"2014","journal-title":"Oncotarget"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/10408441003667514","article-title":"Triclosan: A critical review of the experimental data and development of margins of safety for consumer products","volume":"40","author":"Rodricks","year":"2010","journal-title":"Crit. Rev. Toxicol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1177\/0269881109102644","article-title":"The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia","volume":"24","author":"Park","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/cmdc.201200129","article-title":"Identification of a 17beta-hydroxysteroid dehydrogenase type 10 steroidal inhibitor: A tool to investigate the role of type 10 in Alzheimer\u2019s disease and prostate cancer","volume":"7","author":"Ayan","year":"2012","journal-title":"ChemMedChem"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2174\/156800911795655958","article-title":"Targeting aldose reductase for the treatment of cancer","volume":"11","author":"Tammali","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1089\/omi.2017.0127","article-title":"Transcriptomic-Guided Drug Repositioning Supported by a New Bioinformatics Search Tool: GeneXpharma","volume":"21","author":"Turanli","year":"2017","journal-title":"OMICS"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pcad.2016.10.005","article-title":"Beta-Adrenergic Receptor Blockers in Hypertension: Alive and Well","volume":"59","author":"Frishman","year":"2016","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1189\/jlb.0807531","article-title":"The role of diacylglyceride generation by phospholipase D and phosphatidic acid phosphatase in the activation of 5-lipoxygenase in polymorphonuclear leukocytes","volume":"83","author":"Albert","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1001\/jama.1978.03290230045023","article-title":"Prazosin and clonidine for moderately severe hypertension","volume":"240","author":"Kirkendall","year":"1978","journal-title":"JAMA"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000020246","article-title":"Medical therapy for benign prostatic hyperplasia: A review of the literature","volume":"38","author":"Clifford","year":"2000","journal-title":"Eur. Urol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/jama.1979.03290360053028","article-title":"Prazosin relieves Raynaud\u2019s vasospasm","volume":"241","author":"Waldo","year":"1979","journal-title":"JAMA"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"511","DOI":"10.15252\/emmm.201505421","article-title":"The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCdelta-dependent inhibition of the AKT pathway","volume":"8","author":"Costa","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1593\/neo.07475","article-title":"Prazosin displays anticancer activity against human prostate cancers: Targeting DNA and cell cycle","volume":"9","author":"Lin","year":"2007","journal-title":"Neoplasia"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/187152312803476255","article-title":"Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review","volume":"11","author":"Bacchi","year":"2012","journal-title":"Anti-Inflamm. Anti-Allergy Agents Med. Chem."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fphar.2017.00145","article-title":"Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms","volume":"8","author":"Bilani","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/jnci\/88.1.44","article-title":"Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma","volume":"88","author":"Janik","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.2005.06.005","article-title":"Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4\/CD8 ratio and tumor microenvironment: A multicenter phase II clinical trial","volume":"23","author":"Timar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/ard.51.3.391","article-title":"Analgesic effect of indomethacin shown using the nociceptive flexion reflex in humans","volume":"51","author":"Guieu","year":"1992","journal-title":"Ann. Rheum. Dis."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.23.3.226","article-title":"Indomethacin in the Treatment of Rheumatic Diseases","volume":"23","author":"Percy","year":"1964","journal-title":"Ann. Rheum. Dis."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejmech.2012.08.005","article-title":"COX inhibitors Indomethacin and Sulindac derivatives as antiproliferative agents: Synthesis, biological evaluation, and mechanism investigation","volume":"56","author":"Chennamaneni","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S0959-8049(02)00128-4","article-title":"Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition. identification of novel chemotherapeutic drug resistance modulators","volume":"38","author":"Touhey","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2019.05.008","article-title":"Targeting the Shc-EGFR interaction with indomethacin inhibits MAP kinase pathway signalling","volume":"457","author":"Lin","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"8238","DOI":"10.1074\/jbc.RA118.004415","article-title":"Indomethacin impairs mitochondrial dynamics by activating the PKCzeta-p38-DRP1 pathway and inducing apoptosis in gastric cancer and normal mucosal cells","volume":"294","author":"Mazumder","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1574892812666171129141211","article-title":"Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins","volume":"13","author":"Federica","year":"2018","journal-title":"Recent Pat. Anti-Cancer Drug Discov."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.11-3-306","article-title":"The role of statins in cancer therapy","volume":"11","author":"Hindler","year":"2006","journal-title":"Oncologist"},{"key":"ref_192","first-page":"10","article-title":"The statins as anticancer agents","volume":"9","author":"Chan","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1172\/JCI200519935","article-title":"Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts","volume":"115","author":"Zhuang","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.juro.2011.03.004","article-title":"Statin use and risk of prostate cancer in a population of men who underwent biopsy","volume":"186","author":"Tan","year":"2011","journal-title":"J. Urol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1464-410X.2010.09232.x","article-title":"Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: Results from CaPSURE","volume":"106","author":"Katz","year":"2010","journal-title":"BJU Int."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1002\/cncr.26720","article-title":"Statin use and fatal prostate cancer: A matched case-control study","volume":"118","author":"Marcella","year":"2012","journal-title":"Cancer"},{"key":"ref_197","first-page":"5363","article-title":"Clinical Potential of Statins in Prostate Cancer Radiation Therapy","volume":"37","author":"Hutchinson","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11934-017-0693-8","article-title":"Metformin and Prostate Cancer: A New Role for an Old Drug","volume":"18","author":"Whitburn","year":"2017","journal-title":"Curr. Urol. Rep."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3389\/fnins.2015.00442","article-title":"Metformin and Ara-a Effectively Suppress Brain Cancer by Targeting Cancer Stem\/Progenitor Cells","volume":"9","author":"Mouhieddine","year":"2015","journal-title":"Front. Neurosci."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/j.ejca.2010.06.012","article-title":"Metformin: Taking away the candy for cancer?","volume":"46","author":"Jalving","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.eururo.2014.04.027","article-title":"Metformin use and prostate cancer risk","volume":"66","author":"Preston","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1073\/pnas.1221055110","article-title":"Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth","volume":"110","author":"Hirsch","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-17-0074","article-title":"The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer","volume":"16","author":"Tran","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1152\/physrev.00030.2014","article-title":"Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality","volume":"95","author":"Gallagher","year":"2015","journal-title":"Physiol. Rev."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Bronsveld, H.K., De Bruin, M.L., Wesseling, J., Sanders, J., Hofland, I., Jensen, V., Bazelier, M.T., Ter Braak, B., de Boer, A., and Vestergaard, P. (2018). The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4072-8"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nm.3596","article-title":"Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment","volume":"20","author":"Pollak","year":"2014","journal-title":"Nat. Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cmet.2016.12.009","article-title":"Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex","volume":"25","author":"Howell","year":"2017","journal-title":"Cell Metab."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Circu, M.L., Dykes, S.S., Carroll, J., Kelly, K., Galiano, F., Greer, A., Cardelli, J., and El-Osta, H. (2016). A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151718"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: Beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell. Signal."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jnci\/djr190","article-title":"Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer","volume":"103","author":"Sack","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Dahlmann, M., Kobelt, D., Walther, W., Mudduluru, G., and Stein, U. (2016). S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction. Cancers, 8.","DOI":"10.3390\/cancers8060059"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Ye, T., Xiong, Y., Yan, Y., Xia, Y., Song, X., Liu, L., Li, D., Wang, N., Zhang, L., and Zhu, Y. (2014). The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085887"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.biocel.2015.11.014","article-title":"Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer","volume":"71","author":"Liu","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2017.03.022","article-title":"Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer","volume":"397","author":"Guo","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: Far beyond an antibiotic","volume":"169","author":"Zarzuelo","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1634\/theoncologist.2012-314","article-title":"Repurposing itraconazole as a treatment for advanced prostate cancer: A noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer","volume":"18","author":"Antonarakis","year":"2013","journal-title":"Oncologist"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature02962","article-title":"Hedgehog signalling in prostate regeneration, neoplasia and metastasis","volume":"431","author":"Karhadkar","year":"2004","journal-title":"Nature"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"44045","DOI":"10.1074\/jbc.M111.278754","article-title":"The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells","volume":"286","author":"Nacev","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1021\/acschembio.6b00849","article-title":"Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis","volume":"12","author":"Head","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jid.2018.12.028","article-title":"Itraconazole Induces Regression of Infantile Hemangioma via Downregulation of the Platelet-Derived Growth Factor-D\/PI3K\/Akt\/mTOR Pathway","volume":"139","author":"Chen","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1473-3099(10)70187-0","article-title":"Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: An open-label randomised trial","volume":"10","author":"Smithuis","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/med.21446","article-title":"Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action","volume":"37","author":"Wong","year":"2017","journal-title":"Med. Res. Rev."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2174\/0929867327666200121124404","article-title":"Ferroptosis: A Novel Mechanism of Artemisinin and its Derivatives in Cancer Therapy","volume":"28","author":"Zhu","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcancer.2017.02.009","article-title":"From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy","volume":"46","author":"Efferth","year":"2017","journal-title":"Semin. Cancer Biol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"33425","DOI":"10.1074\/jbc.M114.564567","article-title":"Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin","volume":"289","author":"Yang","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/14740338.2011.566555","article-title":"Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy","volume":"10","author":"Abarientos","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/0961203317727601","article-title":"Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus","volume":"27","author":"Meggitt","year":"2018","journal-title":"Lupus"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrclinonc.2011.71","article-title":"Autophagy as a target for anticancer therapy","volume":"8","author":"Janku","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"Levy","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"17448","DOI":"10.1073\/pnas.0508888102","article-title":"Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors","volume":"102","author":"Gurova","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"95ra74","DOI":"10.1126\/scitranslmed.3002530","article-title":"Curaxins: Anticancer compounds that simultaneously suppress NF-kappaB and activate p53 by targeting FACT","volume":"3","author":"Gasparian","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/0008-5472.CAN-17-2690","article-title":"Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs","volume":"78","author":"Nesher","year":"2018","journal-title":"Cancer Res."},{"key":"ref_236","first-page":"13","article-title":"Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect","volume":"4","author":"Lewiecki","year":"2010","journal-title":"Core Evid."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2016.69.0677","article-title":"Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial","volume":"35","author":"Mason","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"FSO253","DOI":"10.4155\/fsoa-2017-0094","article-title":"Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer","volume":"4","author":"Niraula","year":"2018","journal-title":"Future Sci. OA"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: Pharmacokinetics and pharmacodynamics","volume":"23","author":"Thorn","year":"2013","journal-title":"Pharm. Genom."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1038\/srep07830","article-title":"Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: Comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex","volume":"5","author":"Yu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0960-0760(91)90371-B","article-title":"Suppression of the growth of the androgen-insensitive R3327 HI rat prostatic carcinoma by combined estrogen and antiprogestin treatment","volume":"39","author":"Mobbs","year":"1991","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Tieszen, C.R., Goyeneche, A.A., Brandhagen, B.N., Ortbahn, C.T., and Telleria, C.M. (2011). Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-207"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1464-410X.2008.07509.x","article-title":"A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones","volume":"101","author":"Taplin","year":"2008","journal-title":"BJU Int."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","article-title":"The status of disulfiram: A half of a century later","volume":"26","author":"Suh","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(48)91514-1","article-title":"A drug sensitizing the organism to ethyl alcohol","volume":"2","author":"Hald","year":"1948","journal-title":"Lancet"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.15252\/emmm.201607446","article-title":"BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity","volume":"9","author":"Tacconi","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"e1800136","DOI":"10.1002\/bies.201800136","article-title":"Human Endogenous Formaldehyde as an Anticancer Metabolite: Its Oxidation Downregulation May Be a Means of Improving Therapy","volume":"40","author":"Dorokhov","year":"2018","journal-title":"Bioessays"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.molcel.2015.08.020","article-title":"Endogenous Formaldehyde Is a Hematopoietic Stem Cell Genotoxin and Metabolic Carcinogen","volume":"60","author":"Pontel","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/bjc.2012.442","article-title":"Cytotoxic effect of disulfiram\/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells","volume":"107","author":"Liu","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"109371","DOI":"10.1016\/j.biopha.2019.109371","article-title":"Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation","volume":"118","author":"Guo","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/pros.21247","article-title":"Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth","volume":"71","author":"Lin","year":"2011","journal-title":"Prostate"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/pcan.2013.28","article-title":"Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer","volume":"16","author":"Schweizer","year":"2013","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1158\/0008-5472.CAN-13-3527","article-title":"Copper signaling axis as a target for prostate cancer therapeutics","volume":"74","author":"Safi","year":"2014","journal-title":"Cancer Res."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nature25016","article-title":"Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4","volume":"552","author":"Skrott","year":"2017","journal-title":"Nature"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"g6808","DOI":"10.1136\/bmj.g6808","article-title":"Sirolimus after kidney transplantation","volume":"349","author":"Sharif","year":"2014","journal-title":"BMJ"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1161\/01.CIR.0000033973.06059.04","article-title":"Oral everolimus inhibits in-stent neointimal growth","volume":"106","author":"Farb","year":"2002","journal-title":"Circulation"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0140-6736(03)12275-1","article-title":"Drug-eluting stents in vascular intervention","volume":"361","author":"Fattori","year":"2003","journal-title":"Lancet"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: A new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"15113","DOI":"10.1073\/pnas.2436348100","article-title":"Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling","volume":"100","author":"Brown","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1158\/1078-0432.CCR-10-2285","article-title":"Dual mTORC2\/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors","volume":"17","author":"Altman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jcb.22380","article-title":"RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia","volume":"109","author":"Mancini","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2362.2007.01892.x","article-title":"Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia","volume":"38","author":"Sillaber","year":"2008","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"33549","DOI":"10.18632\/oncotarget.26088","article-title":"The Akt\/mTOR pathway in cancer stem\/progenitor cells is a potential therapeutic target for glioblastoma and neuroblastoma","volume":"9","author":"Bahmad","year":"2018","journal-title":"Oncotarget"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1200\/JCO.2005.03.8851","article-title":"Thalidomide and dexamethasone: A new standard of care for initial therapy in multiple myeloma","volume":"24","author":"Richardson","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/annonc\/mdh300","article-title":"Thalidomide in cancer medicine","volume":"15","author":"Bamias","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/mc.23004","article-title":"The synthetic retinoid ST1926 attenuates prostate cancer growth and potentially targets prostate cancer stem-like cells","volume":"58","author":"Bahmad","year":"2019","journal-title":"Mol. Carcinog."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/10\/1\/15\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:22:25Z","timestamp":1760134945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/10\/1\/15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":267,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["medsci10010015"],"URL":"https:\/\/doi.org\/10.3390\/medsci10010015","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]}}}